MRNA
Moderna, Inc.
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −1.8B | −1.9B | −3.0B | −3.1B | 5.0B | 13.6B | 2.0B | −459M | −331M | −331M | 67M |
| 0.19B | 0.19B | 1.05B | 0.71B | 0.40B | 0.28B | 68M | 32M | 0.11B | 58M | 33M | |
| Free cash flow | −2.0B | −2.1B | −4.1B | −3.8B | 4.6B | 13.3B | 2.0B | −491M | −437M | −390M | 34M |
| Depreciation and amortization | 239M | 211M | 185M | 617M | 348M | 232M | 31M | 31M | 25M | 21M | 15M |
| Stock-based compensation | 464M | 483M | 429M | 305M | 226M | 142M | 93M | 81M | 73M | 40M | 39M |
| Buybacks | — | 2.0M | 0 | 1.15B | 3.33B | 0.86B | 0 | 0 | — | — | — |
| Free cash flow margin | −78.0% | −106.2% | −125.3% | −55.9% | 23.8% | 72.2% | 244.0% | −818.3% | −323.3% | −189.4% | 31.0% |